PMID- 35804447
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1475-2867 (Print)
IS  - 1475-2867 (Electronic)
IS  - 1475-2867 (Linking)
VI  - 22
IP  - 1
DP  - 2022 Jul 8
TI  - A novel signature derived from metabolism-related genes GPT and SMS to predict 
      prognosis of laryngeal squamous cell carcinoma.
PG  - 226
LID - 10.1186/s12935-022-02647-2 [doi]
LID - 226
AB  - BACKGROUND: A growing body of evidence has suggested the involvement of 
      metabolism in the occurrence and development of tumors. But the link between 
      metabolism and laryngeal squamous cell carcinoma (LSCC) has rarely been reported. 
      This study seeks to understand and explain the role of metabolic biomarkers in 
      predicting the prognosis of LSCC. METHODS: We identified the differentially 
      expressed metabolism-related genes (MRGs) through RNA-seq data of The Cancer 
      Genome Atlas (TCGA) and Gene set enrichment analysis (GSEA). After the screening 
      of protein-protein interaction (PPI), hub MRGs were analyzed by least absolute 
      shrinkage and selection operator (LASSO) and Cox regression analyses to construct 
      a prognostic signature. Kaplan-Meier survival analysis and the receiver operating 
      characteristic (ROC) was applied to verify the effectiveness of the prognostic 
      signature in four cohorts (TCGA cohort, GSE27020 cohort, TCGA-sub1 cohort and 
      TCGA-sub2 cohort). The expressions of the hub MRGs in LSCC cell lines and 
      clinical samples were verified by quantitative reverse transcriptase PCR 
      (qRT-PCR). The immunofluorescence staining of the tissue microarray (TMA) was 
      carried out to further verify the reliability and validity of the prognostic 
      signature. Cox regression analysis was then used to screen for independent 
      prognostic factors of LSCC and a nomogram was constructed based on the results. 
      RESULTS: Among the 180 differentially expressed MRGs, 14 prognostic MRGs were 
      identified. A prognostic signature based on two MRGs (GPT and SMS) was then 
      constructed and verified via internal and external validation cohorts. Compared 
      to the adjacent normal tissues, SMS expression was higher while GPT expression 
      was lower in LSCC tissues, indicating poorer outcomes. The prognostic signature 
      was proven as an independent risk factor for LSCC in both internal and external 
      validation cohorts. A nomogram based on these results was developed for clinical 
      application. CONCLUSIONS: Differentially expressed MRGs were found and proven to 
      be related to the prognosis of LSCC. We constructed a novel prognostic signature 
      based on MRGs in LSCC for the first time and verified it via different cohorts 
      from both databases and clinical samples. A nomogram based on this prognostic 
      signature was developed.
CI  - (c) 2022. The Author(s).
FAU - Shen, Yujie
AU  - Shen Y
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China.
FAU - Huang, Qiang
AU  - Huang Q
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China.
FAU - Zhang, Yifan
AU  - Zhang Y
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China.
FAU - Hsueh, Chi-Yao
AU  - Hsueh CY
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China. hsuehchiyao@gmail.com.
FAU - Zhou, Liang
AU  - Zhou L
AD  - Department of Otorhinolaryngology, Eye & ENT Hospital, Fudan University, 
      Shanghai, 200031, China. liang.zhou@fdeent.org.
LA  - eng
GR  - No. 81972529/National Natural Science Foundation of China/
GR  - No. 19411961300/Science and Technology Commission of Shanghai Municipality/
PT  - Journal Article
DEP - 20220708
PL  - England
TA  - Cancer Cell Int
JT  - Cancer cell international
JID - 101139795
PMC - PMC9270735
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma
OT  - Metabolism
OT  - Nomogram
OT  - Prognosis
OT  - Tissue microarray
COIS- The authors declare that they have no competing interests.
EDAT- 2022/07/09 06:00
MHDA- 2022/07/09 06:01
PMCR- 2022/07/08
CRDT- 2022/07/08 23:50
PHST- 2022/03/30 00:00 [received]
PHST- 2022/06/28 00:00 [accepted]
PHST- 2022/07/08 23:50 [entrez]
PHST- 2022/07/09 06:00 [pubmed]
PHST- 2022/07/09 06:01 [medline]
PHST- 2022/07/08 00:00 [pmc-release]
AID - 10.1186/s12935-022-02647-2 [pii]
AID - 2647 [pii]
AID - 10.1186/s12935-022-02647-2 [doi]
PST - epublish
SO  - Cancer Cell Int. 2022 Jul 8;22(1):226. doi: 10.1186/s12935-022-02647-2.